BREAKING
Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 39 minutes ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 3 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 5 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 6 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 6 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 7 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 9 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 9 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 10 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 10 hours ago Anavex Q1 2026 Earnings Rise: Breakthrough Drug Nears 39 minutes ago Dynatrace Shares Rise After Q3 Fiscal 2026 Results Beat Guidance 3 hours ago Eli Lilly and Company (LLY) to acquire Orna Therapeutics 5 hours ago Earnings Summary: Becton, Dickinson and Company Q1 FY26 adjusted earnings decline 15% 6 hours ago Earnings Summary: Highlights of Apollo Global Management’s (APO) Q4 FY25 report 6 hours ago Earnings Summary: Loews Corporation reports sharp increase in Q4 FY25 profit 7 hours ago Plains All American weakens as NGL divestiture and cost cuts frame muted 2026 growth 9 hours ago Plains All American Streamlines, Targets Crude Growth Amid NGL Exit 9 hours ago Operational Efficiency Powers MGY to Historic Production and Dividend Lift 10 hours ago Johnson Outdoors Hooks 31% Revenue Gain, Operating Loss Narrows 10 hours ago
ADVERTISEMENT
AlphaGraphs

PFE Earnings: All you need to know about Pfizer’s Q2 2023 earnings results

Pfizer Inc. (NYSE: PFE) reported second quarter 2023 earnings results today. Revenues decreased 54% year-over-year to $12.7 billion. Reported net income declined 77% to $2.3 billion, or $0.41 per share, compared to last year. Adjusted EPS fell 67% to $0.67. While earnings beat expectations, revenue fell short of estimates. For the full year of 2023, […]

August 1, 2023 1 min read

Pfizer Inc. (NYSE: PFE) reported second quarter 2023 earnings results today.

Revenues decreased 54% year-over-year to $12.7 billion.

Reported net income declined 77% to $2.3 billion, or $0.41 per share, compared to last year. Adjusted EPS fell 67% to $0.67.

While earnings beat expectations, revenue fell short of estimates.

For the full year of 2023, revenues are expected to range between $67-70 billion while adjusted EPS is estimated to range between $3.25-3.45.

ADVERTISEMENT

The stock dropped 1% in premarket hours on Tuesday following the report.

Prior performance

ADVERTISEMENT